bioRxiv Science⌕ Search

Biology subjects

Cabrera, R. M.

Publications and source records attributed to Cabrera, R. M..

3 recordsLinked to original sources

Decoding the RNA Splicing Network in HNRNPH2-R114W Brain Organoids

Autism spectrum disorder and related neurodevelopmental diseases are increasingly linked to disrupted RNA processing during corticogenesis, yet resolving variant-specific mechanisms during early human development remains challenging. We generated isogenic cerebral organoids from a patient iPSC line carrying the HNRNPH2-R114W mutation and its CRISPR-corrected counterpart. Developmental validation by time-course imaging, followed by bulk RNA-Seq at day 20, showed comparable early differentiation and corticogenesis. Genotype was the primary determinant of global expression state, with organized remodeling of neuronal and metabolic programs. Splicing analyses demonstrated junction-dominant dysregulation, where 6,310 junctions exhibited significant differential usage. Junction-level resolution revealed a dominant genotype-related signal than exon-centric analysis. A structural docking model shows HNRNPH2 RNA recognition motifs 1-3 within a spliceosomal context and position residue R114 at an RNA-contact cleft, consistent with direct disruption of RNA engagement by R114W. Integrating differential expression with event- and isoform-level evidence prioritized convergent regulatory hubs enriched for axon guidance, synaptic signaling, and extracellular matrix programs. Single-cell RNA-Seq deconvolution revealed modest compositional shifts that do not account for the magnitude of transcriptional and splicing alterations. Collectively, these data support that HNRNPH2-R114W drives pervasive, junction-centered RNA rewiring in human cortical organoids and defines isoform-level endpoints for mechanistic studies and therapeutic testing in an isogenic developmental model.

neuroscience↗

Dolutegravir Developmental Toxicity is Mitigated by Magnesium and Folate in Zebrafish Embryos

Integrase-strand-transfer inhibitors have transformed HIV therapy, yet the widely prescribed drug dolutegravir (DTG) has been linked to developmental toxicity and its teratogenic mechanism remains uncertain. Here we use zebrafish to dissect DTG toxicity during early vertebrate development. DTG exposure from 2-4 h post-fertilization (hpf) to 24 hpf produced high mortality and abnormal morphology; co-treatment with folic acid or 5-methyltetrahydrofolate partially restored normal morphology, whereas calcium had no effect. Strikingly, supplementation with magnesium (Mg) rescued DTG-exposed embryos almost as effectively as folate, implicating magnesium availability in protection. In competitive binding assays, Mg increased binding of folate to purified folate receptor (FOLR1) by 30% in the presence of DTG. Maternal-zygotic zebrafish folr1 mutant embryos contained significantly less endogenous folate than wild-type embryos yet displayed marked hypersensitivity to DTG that could not be mitigated by folate supplementation. Critically, magnesium supplementation partially rescued DTG toxicity in folr1 mutants, indicating a Folr1-independent component and placing the free DTG vs Mg-bound DTG balance upstream of folate transport. These results support a model in which free DTG antagonizes FOLR1, and Mg modifies DTG developmental toxicity by both FOLR1 dependent and independent processes. Our work identifies magnesium status as a modifiable determinant of DTG teratogenicity and provides a proof-of-concept zebrafish model that could be adapted for rapid in vivo screening of integrase inhibitors for developmental phenotypes.

developmental biology↗

The Antagonism of Folate Receptor by the Integrase Inhibitor Dolutegravir

Human immunodeficiency virus (HIV) integrase inhibitors are increasingly being used for antiretroviral therapy (ART), and dolutegravir (DTG/Tivicay) has emerged as a leading core agent. In 2018, the Tsepamo study reported a 6- to 9-fold increase for neural tube defect (NTD) risk among the offspring of mothers receiving DTG during early gestation. Maternal folate (vitamin B9) status is the largest known modifier of NTD risk, so we evaluated folate-related mechanisms of action and the critical period for DTG developmental toxicity. Folate receptor (FOLR1) binding studies indicate DTG is a non-competitive FOLR1 antagonist at therapeutic concentrations. In vitro testing indicates calcium (2mM) increases FOLR1-folate interactions and alters DTG-FOLR1-folate interactions and cytotoxicity. DTG does not inhibit downstream folate metabolism by dihydrofolate reductase (DHFR). Early embryonic exposure to DTG is developmentally toxic in zebrafish, and supplemental folic acid can mitigate DTG developmental toxicity. The results from these studies are expected to inform and guide future animal models and clinical studies of DTG-based ART in women of childbearing age.

pharmacology and toxicology↗